criteria for IgE-mediated allergic anaphylaxis, 13% lacking evidence of positive IgE tests were labelled "non-allergic anaphylaxis". 3% were non-IgE-mediated anaphylaxis. Adherence to guidance was similar to the baseline survey for waiting time for clinic assessment. However, lack of testing for chlorhexidine and latex, non-harmonized testing practices and poor coverage of all possible culprits was confirmed.
Challenge testing may be underused and many have unacceptably delayed assessments, even in urgent cases. Communication or information provision for patients was insufficient, especially for avoidance advice and communication of test results.
Insufficient detail regarding skin test methods was available to draw conclusions regarding techniques.
Conclusion and Clinical Relevance:
Current clinical assessment in the UK is effective but harmonization of approach to testing, access to services and MHRA reporting is needed. Expert anaesthetist involvement should increase to optimize diagnostic yield and advice for future anaesthesia. Dynamic tryptase evaluation improves detection of tryptase release where peak tryptase is <14 lg/L and should be adopted. Standardized clinic reports containing appropriate details of tests, conclusions, avoidance, cross-reactivity and suitable alternatives are required to ensure effective, safe future management options. Clinical Excellence (NICE) CG183 "Drug allergy: diagnosis and management of drug allergy in adults, children and young people". 1 We compared the actual performance in the NAP6 data set with that of the NAP6 baseline survey.
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What we knew about investigations in perioperative anaphylaxis before NAP6
• Tryptase release is seen in most but not all cases of perioperative anaphylaxis, most commonly in the higher grades of reaction (Grade 3-5).
2-9
• There is a poor correlation with reaction grade individually, but higher medians are seen in more severe reactions. 3 • Tryptase levels plateau between 30 and 90 minutes post-reaction. 9 • Dynamic tryptase results may identify tryptase release in more cases than exceeding fixed thresholds of 11.4 or 14 lg/L.
3,10
• Exposure to opioids such as pholcodine may correlate with neuromuscular blocking agent (NMBA) anaphylaxis.
NMBA anaphylaxis is rarely diagnosed in Denmark,
where it is banned, unlike Norway (historically) and the UK.
11,12
• Basal tryptase levels may correlate with severity of anaphylaxis in non-perioperative settings.
13
• The incidence of latex allergy is probably decreasing.
4,14
• Rocuronium may now be a leading cause of NMBA reactions.
15
• Chlorhexidine and teicoplanin are triggers on the rise.
4,15-19
• There is considerable variation in skin testing and no consensus on the best panel and sequence of testing.
| ME TH ODS
NAP6 did not require National Research Ethics Service approval as a Health-Regulatory-Authority-defined service evaluation. All UK NHS and private hospitals undertaking surgery in the UK were invited.
Anaesthetists reported cases in 2 web-based forms: Part A before allergy clinic investigation and Part B after allergy clinic assessment and follow-up. Only cases with both Part A and B were included.
Reports were assessed by the panel in an expert consensus analysis of imputability in exactly the same way as in an allergy clinic, but in a structured process involving consensus between multiple experts in allergy and anaesthesia and a multistage review as described in the NAP6 papers (Table 1) . This is similar to Bayesian approaches to assigning drug imputability 20, 21 .
The clinical history and experience of the panel members led the diagnosis and test results were utilized as supporting evidence as is normal practice, but utilizing defined criteria. 21 The outcomes for this paper were classified as "allergic anaphylaxis" when parameters strongly supported the diagnosis included relevant IgE sensitization, and as "non-allergic anaphylaxis" when relevant IgE sensitization could not be demonstrated as summarized in Table 1 . Seventeen cases where testing was not available but the reactions had a high probability of allergic aetiology were included in the allergic group despite lack of evidence of sensitization. It is acknowledged that the lack of ability to demonstrate sensitization is not an indication that the reaction was not IgE-mediated, due to the influence of time and the known deficiencies of all the tests, including tryptase sampling.
In all other respects, "allergic" and "non-allergic" cases were identical.
The panel attributed a level of certainty to their diagnosis (Definite; Probable; Possible; Low/Unable to identify). Only Definite or Probable culprits were used for numerical analysis. This structured process was used in an attempt to avoid "outcome bias" (where the known poor outcome leads to an unreasonably harsh judgement), "hindsight bias" (where retrospective review leads to a tendency to believe that an adverse outcome was predictable or avoidable) and "groupthink" (where a desire to agree within groups leads to a lack of independent scrutiny).
In judging quality of care, we referred to guidelines from AAGBI 22 , NICE CG183 23 and BSACI 24 to measure deviation from standards of care. 1 Overall quality of care (management, clinic referral and allergy clinic investigation) were judged as "good," "poor,"
"good and poor" or "unassessable" based on adherence to guidelines and ultimately by panel consensus.
Grade of reaction was reviewed against criteria in the NAP6 epidemiology paper, consistent with WAO definitions. 25 Grade 3, bronchospasm or hypotension (systolic nadir ≥50 mm Hg) together with One hundred and seventy-five (76%) were taken within the hour, consistent with the ANZAAG (Australian and New Zealand Anaesthetic Allergy Group) guidelines ( Figure 1A ). 1, 14, [22] [23] [24] Twenty-three (3%) T2 samples were taken within 60 and 74 (32%) at <120 minutes, consistent with BSACI guidance, rising to 43% within 3 and 71% within 6 hours. One hundred and sixty-eight (73%) had satisfactory T3 >24 hours baseline samples, 12% were too early <20 hours. Table 2 ).
| Tryptase levels

| Tryptase and triggers
The median Tp/T1 appeared lowest for chlorhexidine and highest for suxamethonium ( Figure 2 , Material S2). There were statistically significant differences (P = .002-.4) for both T1 and Tp for both distributions and medians using Mann-Whitney U test and KruskalWallis ANOVA on SPSS for chlorhexidine against all other triggers. Tp Tryptase Peak (mcg/L) 
T A B L E 2 Median tryptase values by reaction grade
F I G U R E 2
| Tryptase and severity
Statistically significant differences in distribution and medians were seen between Grade 3 and 4 reactions (P = .001, Figure 3 , Material S3). There was no correlation between T1 and nadir oxygen saturation, lowest blood pressure recorded or the total dose of adrenaline given (Material S4).
| Tryptase and reaction speed
Reactions were slowest for chlorhexidine and fastest for suxamethonium, muscle relaxants and the antibiotics teicoplanin 
| Tryptase levels in allergic and non-allergic groups
Median T1 levels were not significantly higher in allergic anaphylaxis (P > .05, Figure 5 ) vs non-allergic" anaphylaxis (where specific
IgE sensitization could not be demonstrated). Overall distributions and ranges were similar. Furthermore, the allergic and non-allergic cases had indistinguishable clinic phenotypes, tryptases, triggers and outcomes. The only difference was the inability to reliably detect sIgE. Table 3 ). DT was also useful at an 11.4 lg/L (95th centile) threshold.
| Referrals to allergy clinics
A total of 190 (71%) of referrals were by the index anaesthetist, 45 by another anaesthetist (total 88% adherent), 17 by surgeons, 2 by GPs, 6 by others and 14 not specified. Panel graded 60% of referrals good, 19% good and poor, 9.5% poor and 11.6% 
| Timeliness of assessment of urgent cases
Urgent cases were not seen quickly. Eleven of 29 (38%) waited NMBA panels were inadequate in 55%, skin prick testing in 69%
and intradermal testing in 76%. Forty-one had appropriate avoidance advice and 66%-76% had appropriate letters to GP, patient and anaesthetist. Hazard warning advice was issued to 41%. 10 patients were still at potential risk after investigation: 7 from defective avoidance advice and 4 due to poor communication. Two anaesthetists received insufficient information to plan safe future anaesthetics.
Few had investigated all potential culprits. Latex, opioids, chlorhexidine, gentamicin, ketamine, propofol, dexamethasone, midazolam, rocuronium and metronidazole were all omitted, and in 8, challenge testing was appropriate but not undertaken. 
| Written communication
Adherence to communication standards was much worse than the NAP6 baseline survey ( Figure 6B ). Provision of written information T1 Tryptase (mcg/L) F I G U R E 4 Continued to patients before clinic was rare, and information on patient support groups was only 25%. Written safe alternatives were identified in only 28% (74/266) and avoidance was provided to 63%
(167/266).
| Hazard alert provision
The NAP6 baseline survey suggested 95% of patients were issued alert information but only 21% were issued allergy alerts in NAP6; 14% by an anaesthetist and 7% by the clinic ( Figure 6B ).
| Testing strategies
Use of SPT and IDT were similar to the NAP6 baseline. Use of the NAP6 NMBA panel and latex was less than the baseline survey (Figure 6C) . The appropriateness of the tests used was assessed (Figure 6D) . Generally, the panels were not comprehensive and often missed potential culprits. Use of single tests (or tests to a single set of closely related agents only) was most common for suspected dye reaction and antibiotics. Forty potential drug culprits were omitted in the 184 reviewed cases (Material S6). Ondansetron, latex, chlorhexidine and fentanyl were the most frequently omitted. 
| NMBA
Where the NAP6 NMBA panel was not used, the most common combination was atracurium and rocuronium testing. Suxamethonium was the most common omission.
| Chlorhexidine
Routine use of chlorhexidine testing is less common than reported in the NAP6 baseline, only two-thirds of patients having even single modality testing.
| Latex
Only 31% were tested, mostly by sIgE blood tests. Only 1 weak latex IgE positive was seen, and only 1 of 12 SPT was positive.
| Multiple positivity to other agents
This was common (Material S7). No distinction is made between pre-event potential cross-reactive sensitization or primary occurrence of a second sensitization as we have no means of evidencing that supposition.
| Skin test concentrations
Ninety of 266 (34%) had IDT results reported; 135 (51%) SPT and 188 (71%) sIgE (Material S7). Little data on use of non-irritant concentrations were reported.
| Specific IgE (sIgE) blood tests
A limited range of the available sIgE tests was used including chlorhexidine, penicillins and latex. Few centres reported use of thiocholine (suxamethonium) or morphine/pholcodine testing. Local anaesthetic and latex sIgE were occasionally performed. Chlorhexidine and penicillin sIgE were frequently positive. Many potentially relevant sIgE tests were not used at all in NAP6 (Material S6).
Pholcodine exposure is rarely queried or recorded in UK practice in line with the baseline survey. Eighty-seven 266 (33%) reported no exposure. Pholcodine or morphine (quaternary ammonium groups) was only tested in 4.
| Challenge testing
Twenty-four cases reported the results of challenges (Material S8).
In 10 of these, the panel thought the challenges were incomplete (missing relevant drugs) or inappropriate (in at least one case potentially exposing a patient to an unnecessary risk). 
| Future risk estimates
| Accuracy of diagnosis
| Overall quality of allergy clinic assessment
The panel noted that all potential culprits had been adequately investigated in only 27%. Fifty-four per cent of assessments were good (9.5%) or good and poor (45%); 37% were judged poor. Most 
| Avoidable causal factors were identified in a few cases
Only 3 events were judged avoidable. There were few incidences of failed risk factor identification in preoperative history taking (3), recording or ignoring of relevant information in pre-intervention allergy history (6), previous reaction (3) or possible cross-reactivity (3). These included administration of diclofenac to a NSAID-sensitive individual, chlorhexidine or penicillin to an allergic patient and likely unnecessary coadministration of both co-amoxiclav and teicoplanin.
| MHRA
Only 21% of 266 cases were reported to the MHRA, in contrast to 80% who reported to the local incident system (Material S9).
| DISCUSSION
Eighty-five per cent of those with an identified trigger had evidence of an IgE-mediated reaction on skin or blood testing. Most referrals were by anaesthetists and were consistent with BSACI 24 and AAGBI 22 guidelines, but provision of information to the clinic was suboptimal.
Clinics were unable to make timely assessments for most cases.
Patients were rarely seen at 6 weeks and the excessive waiting times noted in the baseline clinic survey were confirmed. Delay in treatment was common for both urgent and non-urgent cases and underlined the need for better service provision and rapid referral protocols. No reliable distinction between allergic and non-allergic aetiologies can be made on the basis of skin or blood testing in delayed assessments, as skin testing and sIgE can become negative with time. There were no obvious differences between the clinical phenotypes, the triggers, the tryptase results or the outcomes for the patient labelled allergic or non-allergic anaphylaxis.
Approximately 400-600 Grade 3-5 cases are expected annually in the UK, similar to previously reported estimates [3] [4] [5] [6] and the NAP6 baseline survey. 1 NAP6 received 266 completed and interpretable 2-part reports from the UK. This suggests some under-reporting. 3, 25 Tryptase sample timing was often suboptimal, sometimes too late to estimate peak tryptase. NAP6 data shows rapid falls within 30 minutes and support BSACI and AAGBI Guidelines (1st sample immediately post-reaction, 2nd at 1-2 hours, plus a 24-hour baseline. 20, 24 Second samples within 6 hours can still be informative (ANZAAG guidelines suggest 1-, 4-and 24-hour samples).
2,14
Ten per cent had elevated baseline tryptase suggesting mastocytosis or raised alpha tryptase due to gene duplication now sometimes referred to as hyper-alpha tryptasaemia syndrome (HATS). 26 It is impossible to verify that these are truly raised, due to the variation in baseline sampling and lack of follow-up samples. No patient was reported to have had known mastocytosis, and the significance of the single patient with an apparent baseline tryptase of 159 mg/L is unknown. Sample mislabelling is known to be common and an equally likely explanation.
Basal tryptase levels did not correlate with severity or grade of reactions, unlike the weak correlation in venom anaphylaxis. 13 Where resuscitation interferes with timely sampling, prompt liaison with the laboratory to retrieve acute biochemistry or haematology samples may be a practical alternative: serum or plasma is satisfactory. Tests can be performed on very low volumes.
Pre-procedure samples also provide effective baseline levels.
Median Tp/T1 results by reaction grade were similar to those previously reported. 3 Higher values appeared to be more strongly Multiple positivity to other agents was common in IDT, SPT and less so for sIgE testing (Material S6). This confirms previous observations in UK cohort. 18 The NAP6 data set extends this observation of multiple positivity to cases of teicoplanin, rocuronium and suxamethonium allergy. This has implications for order and modality of testing, the need to test for all potential culprits and critical appraisal of the imputability of each potential trigger.
Latex is not a cause of perioperative anaphylaxis in NAP6, unlike chlorhexidine. Latex allergy has been falling in France since the late 1990's. 31 Latex-free theatres and hospitals are now common in the UK and new sensitizations unlikely.
Normal clinical diagnosis is a Bayesian process, the NAP6 panel diagnosis mimics and strengthens this approach by utilizing a methodology that ensures a consensus of multiple experts via independent structured reviews of the evidence. The NAP6 panel diagnosis and the clinic diagnosis agreed more frequently than published for the best Bayesian methods in general drug allergy. 20, 32 The ability to recognize the culprit may be assisted by the rapid presentation of perioperative reactions.
Excessive avoidance advice may also be harmful. Failure to offer appropriate IDT and challenge testing resulted in inappropriate avoidance in some cases. Inappropriate avoidance advice because of a low probability of penicillin allergy (not confirmed on clinic evaluation) was a problem and resulted in reactions to teicoplanin. 33 Use of teicoplanin as a penicillin substitute is increasing; proper pre-procedure evaluation for true penicillin allergy may reduce this. If penicillin avoidance advice is given, specific advice should also be given on safe alternatives.
MHRA reporting was poorer than the baseline survey. Reporting through the index anaesthetist (AAGBI guideline) is problematic if identification of culprit may change. BSACI expects the allergy clinic to report, but risks duplicate reporting of differing conclusions.
Ensuring MHRA report ID is provided in clinic letters, or nominating a departmental anaesthetist to report after final clinic assessment is potential solutions.
Comprehensive and safe future avoidance advice was often lacking, perhaps due to inadequate communication or detail in the correspondence or conclusions issued by the clinic.
Allergen challenge testing is the ultimate arbiter of tolerability, but is problematic in perioperative investigations. There were few challenges reported in NAP6, mostly to oral penicillins or intravenous teicoplanin. Three of four teicoplanin challenges were positive.
NMBA challenges are rarely done in the UK, although are performed in Denmark (where NMBA allergy is rare, and the risks may be different).
Alternatively, challenge tolerance to alternative drugs can be established to facilitate other anaesthetic approaches. This was used by some centres. In conclusion, NAP6 shows that adherence to existing guidelines is poor and confirms deficiencies in service availability, capacity, harmonization of investigation and reporting.
The main areas for improvement are
• Improved access to services in a timely manner.
• Reduced waiting times to meet the ideal of 6-8 weeks post-reaction.
• No patient should have to undergo non-urgent surgery without a completed allergy clinic assessment.
• Harmonization of use of testing and imputability assessment.
• Improved communication of diagnosis and clear safe instructions for future safe anaesthesia, with involvement of anaesthetists in clinic activities to achieve this.
• All potential culprits should be tested by all relevant test modalities (SPT, IDT, sIgE and where appropriate challenge testing) as modalities are not always concordant.
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• More data on the predictive values of different modes of testing using standardized methods are required for all triggers.
• Clarity and unambiguity of guideline recommendations are essential.
• Better standardized clinic reports should be developed to encourage reporting of all the relevant information to include, drugs identified, type of reaction, drugs to avoid, safe alternatives, tests used and results: to both anaesthetists, general practitioners and patients (Material S10).
• Outcomes of these urgent investigations should be clearly and reliably communicated to the anaesthetist.
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